Literature DB >> 20890703

Cytotoxic effect of clodronate and zoledronate on the chondrosarcoma cell lines HTB-94 and CAL-78.

Arne Streitbuerger1, Marcel Henrichs, Helmut Ahrens, Claudia Lanvers-Kaminzky, Francois Gouin, Georg Gosheger, Jendrik Hardes.   

Abstract

The wide surgical tumour resection is the only effective treatment in chondrosarcoma. However, a major problem remains the high rate of local recurrences and metastases due to the lack of adjuvant therapies. In this study the cytotoxic effect of the bisphosphonate clodronate (0.1-1000 μM) and zoledronate (0.1-1000 μM) in different concentrations on two chondrosarcoma cell lines (HTB-94 and CAL-78) has been investigated. After an incubation period of 48, 72 and 96 hours the chondrosarcoma cell viability was measured as the MTT-proliferation rate. In concentrations of >1 μm zoledronate the cell activity was reduced by up to 95% for the CAL-78 cells. Further, zoledronate has been more effective in lower concentrations than clodronate in the reduction of cell viability for both cell lines. However, clodronate showed significant cytotoxic effects in high concentrations and after longer incubation periods. Further research is necessary, but in the light of these results bisphosphonates may also play a role in the treatment of chondrosarcomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20890703      PMCID: PMC3167464          DOI: 10.1007/s00264-010-1130-5

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  28 in total

1.  Risk factors for survival and local control in chondrosarcoma of bone.

Authors:  F Fiorenza; A Abudu; R J Grimer; S R Carter; R M Tillman; K Ayoub; D C Mangham; A M Davies
Journal:  J Bone Joint Surg Br       Date:  2002-01

Review 2.  Bisphosphonates in cancer therapy.

Authors:  Jonathan R Green
Journal:  Curr Opin Oncol       Date:  2002-11       Impact factor: 3.645

3.  Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.

Authors:  Sanna S Virtanen; H Kalervo Väänänen; Pirkko L Härkönen; Päivi T Lakkakorpi
Journal:  Cancer Res       Date:  2002-05-01       Impact factor: 12.701

4.  Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival.

Authors:  François Gouin; Benjamin Ory; François Rédini; Dominique Heymann
Journal:  Int J Cancer       Date:  2006-09-01       Impact factor: 7.396

5.  The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro.

Authors:  J Sonnemann; V Eckervogt; B Truckenbrod; J Boos; W Winkelmann; F van Valen
Journal:  Anticancer Drugs       Date:  2001-06       Impact factor: 2.248

6.  Bisphosphonates--mechanisms of action in multiple myeloma.

Authors:  C M Shipman; M J Rogers; K Vanderkerken; B Van Camp; R Graham; G Russell; P I Croucher
Journal:  Acta Oncol       Date:  2000       Impact factor: 4.089

Review 7.  Bisphosphonates in the treatment of malignant bone disease.

Authors:  J R Berenson; A Lipton
Journal:  Annu Rev Med       Date:  1999       Impact factor: 13.739

8.  The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.

Authors:  T Hiraga; P J Williams; G R Mundy; T Yoneda
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

Review 9.  Direct effects of bisphosphonates on breast cancer cells.

Authors:  Siddhika G Senaratne; Kay W Colston
Journal:  Breast Cancer Res       Date:  2001-11-14       Impact factor: 6.466

10.  The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.

Authors:  S P Jagdev; R E Coleman; C M Shipman; A Rostami-H; P I Croucher
Journal:  Br J Cancer       Date:  2001-04-20       Impact factor: 7.640

View more
  5 in total

1.  Effect of compressive loading and incubation with clodronate on the RANKL/OPG system of human osteoblasts.

Authors:  Sarah Grimm; Christian Walter; Andreas Pabst; Jutta Goldschmitt; Heinrich Wehrbein; Collin Jacobs
Journal:  J Orofac Orthop       Date:  2015-11       Impact factor: 1.938

2.  Vγ9Vδ2 T cells and zoledronate mediate antitumor activity in an orthotopic mouse model of human chondrosarcoma.

Authors:  L Sun; Y Li; Z Jiang; J Zhang; H Li; B Li; Z Ye
Journal:  Tumour Biol       Date:  2015-12-16

Review 3.  Chondrosarcoma-from Molecular Pathology to Novel Therapies.

Authors:  Agnieszka E Zając; Sylwia Kopeć; Bartłomiej Szostakowski; Mateusz J Spałek; Michał Fiedorowicz; Elżbieta Bylina; Paulina Filipowicz; Anna Szumera-Ciećkiewicz; Andrzej Tysarowski; Anna M Czarnecka; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

4.  99mTc-NTP 15-5 assessment of the early therapeutic response of chondrosarcoma to zoledronic acid in the Swarm rat orthotopic model.

Authors:  Elisabeth Miot-Noirault; Emmanuelle David; Aurélien Vidal; Caroline Peyrode; Sophie Besse; Marie-Mélanie Dauplat; Marie-Françoise Heymann; François Gouin; Jean-Michel Chezal; Dominique Heymann; Françoise Rédini
Journal:  EJNMMI Res       Date:  2013-05-20       Impact factor: 3.138

Review 5.  Bisphosphonate conjugation for bone specific drug targeting.

Authors:  Kristen B Farrell; Alexander Karpeisky; Douglas H Thamm; Shawn Zinnen
Journal:  Bone Rep       Date:  2018-07-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.